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Abstract
OBJECTIVES: While transcatheter aortic valve implantation (TAVI) has rapidly evolved for the treatment of aortic valve disease, the current-
ly used bioprostheses are prone to continuous calciﬁc degeneration. Thus, autologous, cell-based, living, tissue-engineered heart valves
(TEHVs) with regeneration potential have been suggested to overcome these limitations. We investigate the technical feasibility of combin-
ing the concept of TEHV with transapical implantation technology using a state-of-the-art transcatheter delivery system facilitating the
exact anatomical position in the systemic circulation.
METHODS: Trileaﬂet TEHVs fabricated from biodegradable synthetic scaffolds were sewn onto self-expanding Nitinol stents seeded with
autologous marrow stromal cells, crimped and transapically delivered into the orthotopic aortic valve position of adult sheep (n = 4) using
the JenaValve transapical TAVI System ( JenaValve, Munich, Germany). Delivery, positioning and functionality were assessed by angiog-
raphy and echocardiography before the TEHV underwent post-mortem gross examination. For three-dimensional reconstruction of the
stent position of the anatomically oriented system, a computed tomography analysis was performed post-mortem.
RESULTS: Anatomically oriented, transapical delivery of marrow stromal cell-based TEHV into the orthotopic aortic valve position was suc-
cessful in all animals (n = 4), with a duration from cell harvest to TEHV implantation of 101 ± 6 min. Fluoroscopy and echocardiography dis-
played sufﬁcient positioning, thereby entirely excluding the native leaﬂets. There were no signs of coronary obstruction. All TEHV tolerated
the loading pressure of the systemic circulation and no acute ruptures occurred. Animals displayed intact and mobile leaﬂets with an ad-
equate functionality. The mean transvalvular gradient was 7.8 ± 0.9 mmHg, and the mean effective oriﬁce area was 1.73 ± 0.02 cm².
Paravalvular leakage was present in two animals, and central aortic regurgitation due to a single-leaﬂet prolapse was detected in two,
which was primarily related to the leaﬂet design. No stent dislocation, migration or affection of the mitral valve was observed.
CONCLUSIONS: For the ﬁrst time, we demonstrate the technical feasibility of a transapical TEHV delivery into the aortic valve position
using a commercially available and clinically applied transapical implantation system that allows for exact anatomical positioning. Our data
indicate that the combination of TEHV and a state-of-the-art transapical delivery system is feasible, representing an important step
towards translational, transcatheter-based TEHV concepts.
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INTRODUCTION
Transcatheter aortic valve implantation (TAVI) represents an efﬁ-
cient alternative for the treatment of valvular heart disease in the
elderly [1–4], and numerous transfemoral and transapical TAVI
devices are commercially available [1–9]. The concept of anatom-
ically oriented devices has been suggested to be beneﬁcial with
regard to delivery, positioning and the avoidance of coronary
obstruction (CO) [2, 5–7, 10].
However, despite these rapid technological advances, the cur-
rently utilized prostheses for TAVI are bioprosthetic, containing
bovine or porcine tissue, and are thus well known to be accom-
panied by continuous and progressive degeneration, which may
be even accelerated due to structural damage in response to
crimping procedures [11]. To overcome such limitations, heart
valve tissue-engineering (HVTE) technologies comprising repair,
regeneration and growth capacities have been repeatedly sug-
gested. However, a translational, clinically applicable HVTE
concept requires a minimally invasive approach for both cell isola-
tion and valve delivery, ideally completely circumventing highly
technical, logistical and ﬁnancial efforts [12–14]. In this regard, and
based on previously described techniques in the setting of
tissue-engineered vascular grafts [15–18], we have recently intro-
duced a novel, clinically relevant concept of a single-step inter-
ventional approach to implant autologous bone-marrow
mononuclear cell (BMMC)-based tissue-engineered heart valves
(TEHVs) into the pulmonary and systemic circulation of primates
and adult sheep [12–14]. However, while these studies were pri-
marily performed using self-made or generic, non-clinical
concept stent and delivery systems, a translational, clinically HVTE
approach requires the use of state-of-the-art devices, in particular
when addressing the systemic circulation [12, 13].
Table 1: Animal data and preoperative assessment
Parameter Mean ± SD
Body weight (kg) 57.7 ± 2.5
Diameter aortic annulus (mm) 22.9 ± 0.3
Distance to brachiocephalic trunk (mm) 42.1 ± 2.4
Diameter sinus portion (mm) 29.0 ± 1.0
Diameter sinotubular junction (mm) 24.3 ± 1.6
Height of sinus portion (mm) 14.5 ± 0.7
Figure 1: Bone marrow mononuclear cell isolation and TEHV preparation. Sternal bone marrow puncture (A) was performed before the prefabricated, stent-based
polyglycolic-acid coated with 1.75% poly-4-hydroxybutyrate composite matrices (B) were seeded with isolated bone marrow mononuclear cells using ﬁbrin as a cell
carrier (C) prior to transapical delivery (D).
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Therefore, the present study investigates the acute technical
feasibility of combining the BMMC-based single-step HVTE ap-
proach with a clinically used, anatomically oriented state-of-the-
art transapical stent delivery system in an adult sheep model with
particular regard to TEHV in vitro fabrication, delivery, positioning
and acute functionality.
MATERIALS ANDMETHODS
Experimentation approval
All animals received humane care in compliance with the
‘Principles of Laboratory Animal-Care’ as well as with the ‘Guide
for the care and use of laboratory animals’ published by the
National Institutes of Health (publication no. 85-23/revised 1985).
All procedures were approved by the Institutional Ethics
Committee (Approval-11–15).
Scaffold fabrication and integration into the
JenaValve stent
Trileaﬂet heart valve scaffolds were fabricated from non-woven
polyglycolic-acid meshes (PGA; Cellon, Luxembourg), coated with
1.75% poly-4-hydroxybutyrate (P4HB; TEPHA Inc., USA) as previ-
ously described [12–14]. Thereafter, the scaffolds were sewn onto
self-expanding Nitinol stents. The scaffolds were attached to the
inside of the Nitinol stent frames by single interrupted sutures.
Isolation and seeding of ovine autologous BMMCs
Bone marrow mononuclear cells (BMMCs) were isolated via
sternal puncture as previously described and characterized in
accordance with the established protocols [12–14]. Using ﬁbrin as
a cell-carrier (Sigma Chemical, USA), BMMCs were seeded onto
the stented heart valve scaffolds (1.08 ± 0.5 × 106 cells/cm2 valve
leaﬂets), before the stented TEHV was crimped and inserted onto
the JenaValve transapical delivery system ( JenaValve, Munich,
Germany).
Preoperative assessment, planning and sizing
Before implantation, all animals underwent transthoracic echocar-
diography in order to assess the optimal stent size. Prior to the im-
plantation, intraoperative angiography was done to re-conﬁrm
the stent size taking into consideration the following parameters:
diameters of the aortic annulus (AA), sinus portion (SP), the sino-
tubular junction (STJ) and the brachiocephalic trunk (BCT) as well
as the distance to the BCT and the height of the SP (Table 1).
Three animals received a 25-mm stented TEHV (n = 3), while one
animal received a 27-mm stented TEHV (n = 1).
Transcatheter implantation of BMMC-based TEHV
using the JenaValve transapical delivery system
Using the JenaValve transapical delivery system, TEHVs were transa-
pically delivered into the aortic valve position. The valves were
crimped and loaded onto a custom-made, over-the-wire JenaValve
delivery system (outer diameter = 8 mm). Following a mini-
sternotomy and placement of 5/0 Prolene pledgeted, purse string
sutures, the apex of the left ventricle was punctured, and the
TEHVs were delivered into the aortic valve position under ﬂuoro-
scopic control (OECW 9900 Elite GE, Fairﬁeld, USA) applying the
previously described and anatomically oriented JenaValve transapi-
cal delivery technology. After positioning the feelers, the JenaValve
stent was opened in a stepwise fashion under ﬂuoroscopic control.
After full delivery of the TEHV, the appropriate positioning, thereby
fully excluding the native valve, as well as sufﬁcient functionality of
the TEHV, was conﬁrmed by contrast angiography (CT), before the
JenaValve delivery device was carefully removed.
Positioning and functionality
JenaValve stent positioning was assessed using intraoperative CT
(Siemens, Munich, Germany), and in vivo functionality was
evaluated using two-dimensional (2D) and three-dimensional
(3D) echocardiography (Philips Healthcare iE33W xMATRIX
Ultrasound, Netherlands).
Figure 2: Cell characterization and functionality assessment. A representative
patch of ovine bone marrow mononuclear cells (BMMCs) was plated and deriv-
ing ovine bone marrow derived mesenchymal stem cells (oMSCs) were charac-
terized using immunohistochemistry for common oMSC markers (A–L). oMSCs
displayed a characteristic spindle-shaped ﬁbroblastic morphology (M) and
functionally was proven by differentiation of a representative oMSC patch into
the adipogenic and osteogenic lineage (N and O).
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Computed tomography and gross examination
After harvest, cardiac computed tomography was performed to
conﬁrm appropriate stent positioning before the hearts were pro-
cessed for gross examination.
Statistical analysis
Quantitative data are presented as mean ± standard deviation
(SPSS 17.0, IBM, Somers, USA).
RESULTS
Scaffold fabrication, cell isolation and TEHV
preparation
Sternal bone marrow puncture (Fig. 1A) was successful in all
animals with a mean amount of 52 ± 4 ml. polyglycolic-acid
coated with 1.75% poly-4-hydroxybutyrate (PGA-P4HB) compos-
ite matrices could be successfully integrated into the anatomically
oriented stent system using single interrupted sutures (Fig. 1B).
Bone marrow mononuclear cells (BMMCs) were isolated and
seeded using ﬁbrin as a cell carrier (Fig. 1C) before they were
transapically implanted (Fig. 1D). A representative patch of ovine
bone marrow mononuclear cells (BMMCs) was plated and deriv-
ing ovine bone marrow derived mesenchymal stem cells (oMSCs)
were characterized using immunohistochemistry for common
ovine MSC markers (Fig. 2A–L). Ovine MSCs displayed a charac-
teristic spindle-shaped ﬁbroblastic morphology (Fig. 2M) and
functionality was proven by differentiation into the adipogenic
and osteogenic lineage (Fig. 2N and O).
Transcatheter delivery of BMMC-based TEHV using
the JenaValve transapical delivery system
Delivery and positioning intraoperative complications.
Transapical aortic valve delivery and deployment of BMMC-based
TEHV utilizing the JenaValve system could be performed
successfully in all animals (n = 4; Fig. 3, Supplementary Video 1). In
brief, the aortic root was visualized (Fig. 2A) before the loaded
JenaValve device was introduced into the left ventricle and
advanced into the aortic root (Fig. 3B and C). Under constant
angiography guidance, the delivery process of the JenaValve
delivery technology was started by positioning of the feeler arms
into the deepest points of the sinuses (Step 1), which was then
followed by the controlled deployment of the distal stent part
(Fig. 3D–F) and completed by deployment of the proximal part
Figure 3: Fluoroscopy-guided, anatomically oriented transapical delivery of marrow stromal cell-based TEHVs into the aortic valve position. The aortic root was visua-
lized (A), before the TEHV loaded JenaValve Stent System was inserted and positioned (B and C). After positioning, the feelers (D and E), the JenaValve stent was
opened in a stepwise fashion under ﬂuoroscopic control (F and G). After full delivery of the TEHV (H), the appropriate positioning thereby fully excluding the native
valve as well as sufﬁcient functionality of the TEHV was conﬁrmed by CT (I), before the JenaValve delivery device was carefully removed.
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(Fig. 3G and H). Immediately after complete deployment,
appropriate perfusion of the coronaries was assessed and
sufﬁcient valve functionality was evaluated (Fig. 3I, Supplementary
Video 1). During the implantation procedure, all animals were
haemodynamically stable and no major complications such as
bleeding or cardiac arrhythmia occurred during device removal.
As in angiography, TEHV could be successfully positioned in the
orthotopic aortic valve position, thereby fully excluding the native
leaﬂets. The mean duration of the entire procedure, beginning
with cell harvest until TEHV delivery was 101 ± 6 min (Table 2).
Echocardiographic assessment of TEHV. TEHV in vivo
performance was controlled via ﬂuoroscopy (Fig. 3, Supplementary
Video 1) and echocardiography (Fig. 4, Supplementary Video 2).
After implantation, all TEHV (n = 4) tolerated the loading pressure
of the systemic circulation, and no leaﬂet tears or acute ruptures
were detected. Sufﬁcient leaﬂet mobility was present in all animals,
and a sufﬁcient opening and closing pattern along with an
appropriate coaptation area was observed in two animals (Fig. 4A–F,
Supplementary Video 2), while the two others displayed a
single-leaﬂet prolapse that was related to the leaﬂet/valve design
of the TEHV. The mean transvalvular gradient was 7.8 ± 0.9
mmHg, and the mean effective oriﬁce area (EOA) was 1.73 ± 0.02
cm² (Table 2). Two animals displayed mild (n = 1)/moderate (n = 1)
paravalvular leakage (PVL), and the ﬁrst two animals showed
moderate central aortic regurgitation (AR; n = 2) that was related
with the scaffold design and geometry within the stent (Table 2).
As a response to the central AR, the scaffold design was changed
to shorter radial leaﬂet extensions and smaller wall-belly angles to
ensure fully coaptation after delivery. No stent dislocation,
migration or affection of the mitral valve was observed.
Post-mortem computed tomography assessment
and gross examination
Optimal TEHV positioning was conﬁrmed on post-mortem com-
puted tomography of the excised hearts (Fig. 5A–F). Gross examin-
ation displayed the JenaValve stent with the TEHV to be well
integrated into the aortic root and the left ventricular outﬂow
tract. The leaﬂet structures were intact, with well-identiﬁable
cusps, while there were no signs of leaﬂet thickening, shrinking or
thrombus formation (Fig. 5G). Minor structural damage of one
leaﬂet was observed in two TEHV and was either related to the
procedural damage during animal harvest or related to the crimp-
ing procedures involved. In the ﬁrst two animals, the leaﬂets were
positioned in a leaﬂet opening angle of 45–60°, which resulted
Figure 4: Echocardiographic assessment of TEHV functionality. Following implantation, TEHV tolerated the loading pressure of the systemic circulation adequately,
and TEHV functionality was controlled via 2D (A and B), 2D color (C and D) and 3D echocardiography (E and F). TEHV displayed sufﬁcient leaﬂet mobility and a sufﬁ-
cient opening and closing pattern along with an appropriate coaptation area. No stent dislocation, migration or affection of the mitral valve was observed.
Table 2: Intraoperative data and echo findings
Parameter Mean ± SD
Crimping time until TEHV delivery (min) 10 ± 4
Duration of the entire one-step procedure (min) 101 ± 6
TVG mean (mmHg) 7.8 ± 0.9
TVG peak (mmHg) 17.2 ± 2.2
EOA (cm²) 1.73 ± 0.02
Central aortic regurgitationa (n) n = 2
Paravalvular leakageb (n) n = 2
Regurgitation of mitral valve None
Leaflet motionc Normal
Cardiac output (l/min) 5.7 ± 0.3
TEHV: tissue-engineered heart valve; TVG: transvalvular gradient; EOA:
effective orifice area.
aTwo animals presented with moderate central aortic regurgitation.
bOne animal with mild and one animal with moderate paravalvular
leakage.
cTwo animals presented with a single-leaflet prolapse.
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central coaptation gaps due to excess of tissue in the coaptation
area. Therefore, in the following TEHV constructs, the leaﬂet
opening angle was changed to 15–30°, which resulted in reduc-
tion of central regurgitation and improved leaﬂet mobility.
DISCUSSION
This is the ﬁrst report elucidating the principal technical feasibility
of combining a clinically relevant HVTE approach with a clinically
applied, anatomically oriented, latest-generation transapical stent
delivery system. In the setting of an adult sheep model, we were
able to demonstrate that BMMC-based TEHVs can be successfully
implanted into the orthotopic aortic valve position with the
JenaValve stent and delivery system. The implanted TEHV dis-
played sufﬁcient in vivo functionality, and importantly, an optimal
delivery and positioning without any coronary compromise was
achieved when using an anatomically oriented stent and delivery
system.
Transcatheter aortic valve implantation (TAVI) is a valid and
accepted treatment option for the elderly, high-risk patient suffer-
ing from symptomatic aortic valve stenosis [1, 19–22]. Numerous
reports indicate the efﬁcacy of transcatheter approaches along
with the established beneﬁts comprising the avoidance of sternot-
omy and extracorporeal circulation. However, the utilized pros-
thesis of the current TAVI concepts are bioprosthetic and
therefore prone to continuous and generalized degeneration. In
addition, and despite considerable mid-term clinical data [19],
nothing is known about potential crimping-associated structural
damage and its impact on long-term clinical outcome and dur-
ability of these prostheses.
HVTE concepts generating living, autologous heart valve con-
structs have been repeatedly proposed as a potential solution due
to their regeneration and growth capacity and may extend the in-
dication for TAVI to younger patient populations. On the other
hand, and in the light of clinical relevance, previous HVTE con-
cepts have been criticized for their high logistical and ﬁnancial
demands limiting a broad clinical applicability. Ideally, a
Figure 5: Computed tomography analysis and gross examination of TEHV. Post-mortem computed tomography (A and B) and 3D reconstruction analysis (C–E) dis-
played sufﬁcient stent positioning after anatomically oriented transapical delivery of the TEHV. Gross examination of the TEHV displayed intact leaﬂet structures with
well-identiﬁable cusps, while there were no signs of leaﬂet thickening, shrinking or thrombus formation (F).
M.Y. Emmert et al. / European Journal of Cardio-Thoracic Surgery66
translational, clinically relevant HVTE concept comprises minimal-
ly invasive techniques for both cell harvest and valve delivery [14].
Therefore, and based on previously reported technologies in the
setting of tissue-engineered vascular grafts [16–18, 23, 24], we have
recently introduced the novel concept of generating and implant-
ing autologous BMMC-derived TEHV in a single-step intervention.
In a preclinical setting, we were able to demonstrate the feasibility
of this novel technology by replacing pulmonary and aortic valves
of primates [14] and adult sheep [12, 13]. However, in these
studies, only self-made or generic, non-clinical concept stent and
delivery systems were used for transapical delivery, while a transla-
tional, clinically HVTE approach also requires the implementation
of state-of-the-art stent and delivery systems, in particular when
addressing the systemic circulation [12, 13].
Although numerous transcatheter devices have been estab-
lished in the clinical setting [12–14, 25], major concerns associated
with current TAVI systems include on the one hand, mal-
positioning leading to central AR or PVL and on the other hand,
the important risk of CO. In this regard, the utilization of next-
generation, anatomically oriented devices has been suggested to
be beneﬁcial, thereby minimizing the risk of the occurrence of AR,
PVL and CO [14].
Therefore, in this study, we successfully combined our one-step
BMMC-based approach with a state-of-the-art, anatomically
oriented transapical delivery system as a further step towards
translational, clinically relevant HVTE concepts. Importantly, our
results show that the occurrence of mal-positioning and import-
antly, stent dislocation as it was observed in our previous studies
[13, 14], can be successfully minimized when using
state-of-the-art, anatomically oriented transapical systems with
feeler-guided positioning and an active clipping mechanism.
Moreover, the safe and effective JenaValve delivery technology
further simpliﬁed our procedural steps signiﬁcantly when com-
pared with the devices used for valve delivery in our previous
studies [12–14, 25].
In general, the transapical delivery system used in this study has
proven its safety in clinical pilot studies [5, 6] and in particular, its
effectiveness with regard to the minimization of the occurrence of
PVL [5, 6] and although the occurrence of PVL and AR was
encountered in this study, it was primarily related to the scaffold
design and integration within the stent, but not to the Jena Valve
stent or the delivery system itself. After delivery in the ﬁrst two
animals, the TEHV systems revealed moderate central AR, which
was most likely related to the steep belly-wall angle of the con-
structs. Therefore, in the following animals, the radial leaﬂet exten-
sion was decreased before implantation to ensure optimal leaﬂet
coaptation in situ and to prevent central AR. After the delivery of
these two constructs, less regurgitation and higher improved
leaﬂet mobility were observed, suggesting that (i) TEHV native
analogous leaﬂet geometry is indispensable for the optimal func-
tionality of anatomically oriented TEHV systems and (ii) that
too-steep belly-wall angles of TEHV leaﬂets lead to central AR due
to the lack of sufﬁcient leaﬂet coaptation.
Limitations
There are several limitations that need to be mentioned: ﬁrst, the
animal numbers are low, and consecutive studies will need larger
cohorts, particularly when assessing the issue of optimized scaf-
fold designs. In addition, this was an acute study with the primary
aim of assessing the principal technical feasibility of combining
our BMMC-based one-step approach with a state-of-the-art, ana-
tomically oriented transapical stent and delivery system. Further
data are necessary to evaluate the long-term safety and efﬁcacy of
the presented technology.
CONCLUSION
For the ﬁrst time, we demonstrate the technical feasibility of a
transapical marrow stromal cell-based TEHV delivery into the
aortic valve position using an anatomically oriented, clinically
applied transapical implantation system. Our data indicate that
the combination of TEHV and a state-of-the-art transapical deliv-
ery system is feasible, representing an important step towards
translational, transcatheter-based TEHV concepts that may
broaden the indication for TAVI to younger patients. To minimize
central regurgitation and the occurrence of PVL, further scaffold
design and valve geometry optimization are necessary.
SUPPLEMENTARYMATERIAL
Supplementary material (Video 1 and 2) is available at EJCTS online.
Video 1: Fluoroscopy shows functionality of the tissue-engineered
heart valve after anatomically oriented, transapical delivery.
Video 2: Two-dimensional echocardiography after anatomically
oriented, transapical delivery of the tissue-engineered heart valve.
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